Avalo Therapeutics, Inc.
AVTX
$19.94
-$0.31-1.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -69.27% | -- | -- | -- | -66.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -69.27% | -- | -- | -- | -66.37% |
| Cost of Revenue | 58.61% | 53.79% | 273.38% | 1,427.65% | 1,206.13% |
| Gross Profit | -63.21% | -59.92% | -273.38% | -1,427.65% | -3,736.73% |
| SG&A Expenses | 24.86% | 30.12% | 15.74% | 73.69% | 95.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.64% | 46.44% | 103.95% | 180.59% | 212.42% |
| Operating Income | -48.31% | -49.27% | -103.95% | -180.59% | -254.87% |
| Income Before Tax | 61.42% | -232.97% | -121.07% | 89.17% | -330.78% |
| Income Tax Expenses | 14.04% | 178.57% | 128.57% | 14.29% | 1,366.67% |
| Earnings from Continuing Operations | 61.18% | -232.94% | -121.09% | 89.16% | -332.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.18% | -232.94% | -121.09% | 89.16% | -332.65% |
| EBIT | -48.31% | -49.27% | -103.95% | -180.59% | -254.87% |
| EBITDA | -48.95% | -49.21% | -103.24% | -179.82% | -257.15% |
| EPS Basic | 78.10% | -322.12% | -306.15% | 96.05% | 66.03% |
| Normalized Basic EPS | 78.35% | -152.68% | -145.46% | 98.85% | 34.90% |
| EPS Diluted | 78.04% | 22.73% | 50.27% | 96.05% | 83.01% |
| Normalized Diluted EPS | 78.35% | -202.43% | -145.46% | 98.85% | 34.90% |
| Average Basic Shares Outstanding | 78.20% | 152.43% | -53.69% | 1,123.52% | 1,167.19% |
| Average Diluted Shares Outstanding | 78.20% | 29.83% | -53.69% | 1,123.52% | 1,167.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |